Detour On FDA’s “Critical Path:” Safety Issues Divert Agency’s Attention
Executive Summary
FDA has revised its timeline for the "Critical Path" drug development initiative to reflect more pressing matters, including drug safety issues, Acting Deputy Commissioner for Operations Janet Woodcock said
You may also be interested in...
Novartis Sets Out On The Critical Path; Will Others Follow?
Novartis' announcement of research collaborations with FDA is one of the first tangible outcomes of the agency's Critical Path initiative
Novartis Sets Out On The Critical Path; Will Others Follow?
Novartis' announcement of research collaborations with FDA is one of the first tangible outcomes of the agency's Critical Path initiative
FDA Seeks Advisory Role In Facilitating Critical Path Research
FDA expects to play the role of a "neutral referee" to facilitate external research conducted under the agency's Critical Path initiative